2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) Director Marcela V. Maus sold 3,900 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $3.38, for a total transaction of $13,182.00. Following the sale, the director now owns 23,752 shares in the company, valued at $80,281.76. This represents a 14.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
2seventy bio Stock Down 3.4 %
2seventy bio stock opened at $3.11 on Thursday. 2seventy bio, Inc. has a 52-week low of $1.53 and a 52-week high of $6.40. The firm's fifty day moving average is $4.64 and its 200 day moving average is $4.46.
Analyst Ratings Changes
Separately, Morgan Stanley reduced their price target on 2seventy bio from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $9.00.
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
View Our Latest Stock Analysis on 2seventy bio
Hedge Funds Weigh In On 2seventy bio
Several institutional investors have recently made changes to their positions in TSVT. Erste Asset Management GmbH purchased a new position in 2seventy bio during the third quarter valued at $25,000. Readystate Asset Management LP acquired a new stake in 2seventy bio in the 3rd quarter worth about $53,000. SkyView Investment Advisors LLC increased its stake in 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company's stock worth $48,000 after buying an additional 2,500 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of 2seventy bio during the third quarter valued at approximately $64,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of 2seventy bio in the second quarter valued at approximately $52,000. 93.90% of the stock is owned by hedge funds and other institutional investors.
About 2seventy bio
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
